Replimune Group, Inc. (REPL)
REPL moved a median of +0.09% 30 minutes after news, and -0.14% by the close. How REPL actually reacts to news — the realized, point-in-time move the market made, measured across 1,432 labeled events over the last three years with zero look-ahead.
REPL’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.01% | 52% | 1,410 |
| 30-min | +0.09% | 51% | 1,412 |
| 60-min | -0.03% | 46% | 1,412 |
| to close | -0.14% | 48% | 1,358 |
| Middle 50% of REPL reactions | -1.40% to +1.33% |
|---|---|
| Median reaction (30-min) | +0.09% |
| Measured reactions | 1,432 |
Half of all Replimune Group, Inc. news events land between -1.40% and +1.33% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How REPL reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 44 | -0.56% | 39% | -0.75% |
| Analyst downgrades | 45 | -1.62% | 42% | -0.58% |
| Rating reiterations | 50 | -0.75% | 32% | -0.90% |
| Price-target raises | 17 | -0.68% | 35% | -1.72% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how REPL ranks against every other measured name →
That’s how REPL usually reacts — get an email when it moves on news →Email me when REPL moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to REPL's baseline. Nothing else.
Recent REPL events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| REPL DEADLINE - FINAL REMINDER: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Replimune Group, Inc. to Contact the Firm Today | Press release | ACCESS Newswire | +0.15% | +1.31% | |
| Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma | Press release | GlobeNewswire | -0.80% | -4.53% | |
| Form 8-K Replimune Group, Inc. For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | +0.68% | -2.13% | |
| Replimune to Present at the Cantor Global Healthcare Conference 2026 | Press release | GlobeNewswire | -0.19% | -4.38% | |
| Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REPL | Press release | PR Newswire | -0.10% | -1.01% | |
| Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.28% | -3.44% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Bronstein, Gewirtz & Grossman, LLC (REPL) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.07% | -0.60% | |
| Form 10-Q Replimune Group, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.95% | -0.14% | |
| Form 8-K Replimune Group, Inc. For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | -0.59% | -1.45% | |
| Form S-3ASR Replimune Group, Inc. | SEC filing · Form S-3ASR | SEC EDGAR | -1.95% | -0.14% | |
| Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -0.59% | -1.45% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Replimune Group Inc. (REPL) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | -0.19% | -2.25% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Replimune Group Inc. (REPL) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.60% | +1.06% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Replimune Group Inc. (REPL) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.14% | -1.30% | |
| Form 8-K/A Replimune Group, Inc. For: Aug 09 | SEC filing · Form 8-K | SEC EDGAR | -1.79% | -0.15% | |
| Form 8-K Replimune Group, Inc. For: Aug 09 | SEC filing · Form 8-K | SEC EDGAR | +0.83% | — | |
| Replimune Announces Pricing of $150 Million Underwritten Offering | Press release | GlobeNewswire | +0.83% | — | |
| Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – REPL | Press release | Business Wire | +0.83% | — | |
| Form 8-K Replimune Group, Inc. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | -1.23% | -7.23% | |
| Replimune Group Inc. (REPL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.29% | -0.94% | |
| Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen | Press release | GlobeNewswire | -1.23% | -7.23% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Replimune Group Inc. (REPL) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.21% | -1.78% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Replimune Group Inc. (REPL) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | -0.44% | +4.57% | |
| Replimune Group Inc. (REPL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -6.44% | +7.98% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Replimune Group Inc. (REPL) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.38% | +5.76% | |
| Form 8-K Replimune Group, Inc. For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | +7.79% | -0.89% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Replimune Group Inc. (REPL) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | — | — | |
| Form 8-K Replimune Group, Inc. For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form EFFECT Replimune Group, Inc. | SEC filing · Form EFFECT | SEC EDGAR | — | — | |
| Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma | Press release | GlobeNewswire | +7.79% | -0.89% | |
| Form ARS Replimune Group, Inc. For: Mar 31 | SEC filing · Form ARS | SEC EDGAR | -1.07% | +3.05% | |
| Form DEF 14A Replimune Group, Inc. For: Sep 15 | SEC filing · Form DEF | SEC EDGAR | -1.07% | +3.05% | |
| Form DEFA14A Replimune Group, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -1.07% | +3.05% | |
| Form S-3/A Replimune Group, Inc. | SEC filing · Form S-3 | SEC EDGAR | -3.63% | -0.69% | |
| Form PRE 14A Replimune Group, Inc. For: Sep 15 | SEC filing · Form PRE | SEC EDGAR | -0.45% | -1.99% | |
| Form 10-K Replimune Group, Inc. For: Mar 31 | SEC filing · Form 10-K | SEC EDGAR | -2.13% | -2.44% | |
| Form 8-K Replimune Group, Inc. For: Jun 29 | SEC filing · Form 8-K | SEC EDGAR | -2.13% | -2.44% | |
| Form S-8 Replimune Group, Inc. | SEC filing · Form S-8 | SEC EDGAR | -2.13% | -2.44% | |
| Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -2.13% | -2.44% | |
| Form 8-K Replimune Group, Inc. For: Jun 26 | SEC filing · Form 8-K | SEC EDGAR | -3.51% | +13.46% | |
| Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma | Press release | GlobeNewswire | -3.51% | +13.46% | |
| Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting | Press release | GlobeNewswire | +9.97% | +0.78% | |
| Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting | Press release | GlobeNewswire | +9.97% | +0.78% | |
| Form 8-K Replimune Group, Inc. For: May 29 | SEC filing · Form 8-K | SEC EDGAR | +2.80% | +4.85% | |
| Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA | Press release | GlobeNewswire | -0.88% | +9.58% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Replimune Group, Inc. (REPL) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.21% | -1.25% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Replimune Group, Inc. (REPL) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | +0.16% | -1.94% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Replimune Group, Inc. (REPL) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | -0.37% | -2.01% | |
| Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting | Press release | GlobeNewswire | +6.48% | +8.50% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Replimune Group, Inc. (REPL) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +6.48% | +8.50% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the REPL section they belong to.
Where else REPL is measured.
REPL earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK) | 1,452 | +0.01% | 51% |
| GENMARK DIAGNOSTICS (GNMK) | 1,451 | +0.06% | 51% |
| Altimmune, Inc. (ALT) | 1,424 | 0.00% | 48% |
| PerkinElmer, Inc. (PKI) | 1,409 | +0.11% | 56% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Replimune Group, Inc.'s median reaction calculated?
Every labeled REPL news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 1,432 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 51% of REPL's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does REPL's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.